Literature DB >> 23803905

Genetic distribution of noncapsular meningococcal group B vaccine antigens in Neisseria lactamica.

Jay Lucidarme1, Stefanie Gilchrist, Lynne S Newbold, Stephen J Gray, Edward B Kaczmarski, Lynne Richardson, Julia S Bennett, Martin C J Maiden, Jamie Findlow, Ray Borrow.   

Abstract

The poor immunogenicity of the meningococcal serogroup B (MenB) capsule has led to the development of vaccines targeting subcapsular antigens, in particular the immunodominant and diverse outer membrane porin, PorA. These vaccines are largely strain specific; however, they offer limited protection against the diverse MenB-associated diseases observed in many industrialized nations. To broaden the scope of its protection, the multicomponent vaccine (4CMenB) incorporates a PorA-containing outer membrane vesicle (OMV) alongside relatively conserved recombinant protein components, including factor H-binding protein (fHbp), Neisseria adhesin A (NadA), and neisserial heparin-binding antigen (NHBA). The expression of PorA is unique to meningococci (Neisseria meningitidis); however, many subcapsular antigens are shared with nonpathogenic members of the genus Neisseria that also inhabit the nasopharynx. These organisms may elicit cross-protective immunity against meningococci and/or occupy a niche that might otherwise accommodate pathogens. The potential for 4CMenB responses to impact such species (and vice versa) was investigated by determining the genetic distribution of the primary 4CMenB antigens among diverse members of the common childhood commensal, Neisseria lactamica. All the isolates possessed nhba but were devoid of fhbp and nadA. The nhba alleles were mainly distinct from but closely related to those observed among a representative panel of invasive MenB isolates from the same broad geographic region. We made similar findings for the immunogenic typing antigen, FetA, which constitutes a major part of the 4CMenB OMV. Thus, 4CMenB vaccine responses may impact or be impacted by nasopharyngeal carriage of commensal neisseriae. This highlights an area for further research and surveillance should the vaccine be routinely implemented.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23803905      PMCID: PMC3889585          DOI: 10.1128/CVI.00090-13

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  48 in total

1.  Distribution and genetic variability of three vaccine components in a panel of strains representative of the diversity of serogroup B meningococcus.

Authors:  Stefania Bambini; Alessandro Muzzi; Per Olcen; Rino Rappuoli; Mariagrazia Pizza; Maurizio Comanducci
Journal:  Vaccine       Date:  2009-03-10       Impact factor: 3.641

Review 2.  Global epidemiology of meningococcal disease.

Authors:  Lee H Harrison; Caroline L Trotter; Mary E Ramsay
Journal:  Vaccine       Date:  2009-05-27       Impact factor: 3.641

3.  Measuring antigen-specific bactericidal responses to a multicomponent vaccine against serogroup B meningococcus.

Authors:  Marzia M Giuliani; Alessia Biolchi; Davide Serruto; Francesca Ferlicca; Kay Vienken; Philipp Oster; Rino Rappuoli; Mariagrazia Pizza; John Donnelly
Journal:  Vaccine       Date:  2010-05-21       Impact factor: 3.641

4.  Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease.

Authors:  Han-Qing Jiang; Susan K Hoiseth; Shannon L Harris; Lisa K McNeil; Duzhang Zhu; Cuiwen Tan; Adrienne A Scott; Kristin Alexander; Kathryn Mason; Lynn Miller; Ida DaSilva; Michelle Mack; Xiao-Juan Zhao; Michael W Pride; Lubomira Andrew; Ellen Murphy; Michael Hagen; Roger French; Ashoni Arora; Thomas R Jones; Kathrin U Jansen; Gary W Zlotnick; Annaliesa S Anderson
Journal:  Vaccine       Date:  2010-07-07       Impact factor: 3.641

5.  Characterization of fHbp, nhba (gna2132), nadA, porA, and sequence type in group B meningococcal case isolates collected in England and Wales during January 2008 and potential coverage of an investigational group B meningococcal vaccine.

Authors:  Jay Lucidarme; Maurizio Comanducci; Jamie Findlow; Stephen J Gray; Edward B Kaczmarski; Malcolm Guiver; Pamela J Vallely; Philipp Oster; Mariagrazia Pizza; Stefania Bambini; Alessandro Muzzi; Ray Borrow
Journal:  Clin Vaccine Immunol       Date:  2010-04-07

6.  Long-term evolution of antigen repertoires among carried meningococci.

Authors:  Caroline O Buckee; Sunetra Gupta; Paula Kriz; Martin C J Maiden; Keith A Jolley
Journal:  Proc Biol Sci       Date:  2010-02-03       Impact factor: 5.349

7.  Characterization of fHbp, nhba (gna2132), nadA, porA, sequence type (ST), and genomic presence of IS1301 in group B meningococcal ST269 clonal complex isolates from England and Wales.

Authors:  Jay Lucidarme; Maurizio Comanducci; Jamie Findlow; Stephen J Gray; Edward B Kaczmarski; Malcolm Guiver; Elisabeth Kugelberg; Pamela J Vallely; Philipp Oster; Mariagrazia Pizza; Stefania Bambini; Alessandro Muzzi; Christoph M Tang; Ray Borrow
Journal:  J Clin Microbiol       Date:  2009-09-16       Impact factor: 5.948

Review 8.  Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis.

Authors:  Johan Holst; Diana Martin; Richard Arnold; Concepcion Campa Huergo; Philipp Oster; Jane O'Hallahan; Einar Rosenqvist
Journal:  Vaccine       Date:  2009-05-28       Impact factor: 3.641

9.  Phase I safety and immunogenicity study of a candidate meningococcal disease vaccine based on Neisseria lactamica outer membrane vesicles.

Authors:  Andrew R Gorringe; Stephen Taylor; Charlotte Brookes; Mary Matheson; Michelle Finney; Moyra Kerr; Michael Hudson; Jamie Findlow; Ray Borrow; Nick Andrews; George Kafatos; Cariad M Evans; Robert C Read
Journal:  Clin Vaccine Immunol       Date:  2009-06-24

10.  Vaccine preventability of meningococcal clone, Greater Aachen Region, Germany.

Authors:  Johannes Elias; Leo M Schouls; Ingrid van de Pol; Wendy C Keijzers; Diana R Martin; Anne Glennie; Philipp Oster; Matthias Frosch; Ulrich Vogel; Arie van der Ende
Journal:  Emerg Infect Dis       Date:  2010-03       Impact factor: 6.883

View more
  3 in total

1.  Genotypic analysis of meningococcal factor h-binding protein from non-culture clinical specimens.

Authors:  Stephen A Clark; Jay Lucidarme; Lynne S Newbold; Ray Borrow
Journal:  PLoS One       Date:  2014-02-24       Impact factor: 3.240

2.  Virulence genes and previously unexplored gene clusters in four commensal Neisseria spp. isolated from the human throat expand the neisserial gene repertoire.

Authors:  Alan Calder; Chukwuma Jude Menkiti; Aylin Çağdaş; Jefferson Lisboa Santos; Ricarda Streich; Alice Wong; Amir H Avini; Ebrima Bojang; Karththeepan Yogamanoharan; Nivetha Sivanesan; Besma Ali; Mariam Ashrafi; Abdirizak Issa; Tajinder Kaur; Aisha Latif; Hani A Sheik Mohamed; Atifa Maqsood; Laxmi Tamang; Emily Swager; Alex J Stringer; Lori A S Snyder
Journal:  Microb Genom       Date:  2020-08-26

3.  'Be on the TEAM' Study (Teenagers Against Meningitis): protocol for a controlled clinical trial evaluating the impact of 4CMenB or MenB-fHbp vaccination on the pharyngeal carriage of meningococci in adolescents.

Authors:  Jeremy Carr; Emma Plested; Parvinder Aley; Susana Camara; Kimberly Davis; Jenny M MacLennan; Steve Gray; Saul N Faust; Ray Borrow; Hannah Christensen; Caroline Trotter; Martin C J Maiden; Adam Finn; Matthew D Snape
Journal:  BMJ Open       Date:  2020-10-22       Impact factor: 2.692

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.